Investors in Quantum-Si, Inc. (QSI) weren't thrilled with the company's latest report card. The stock slipped in extended trading Tuesday after the protein sequencing specialist posted fourth-quarter revenue that fell well short of what Wall Street was looking for.
Here's the report in a nutshell: the company lost 8 cents per share, which was actually better than the 12-cent loss analysts had forecast. The problem was on the top line. Revenue came in at $451,000, missing the consensus estimate of $762,000. That's a pretty big gap for a company at this stage.
Management tried to put a positive spin on the year. "2025 was a year of significant progress as we continued to advance our technology through multiple new kit launches, expanding the installed base and consumable utilization of our first-generation Platinum Pro system, and delivered on our key strategic goal of demonstrating sequencing on our Proteus prototype system that exceeded our current technology across all key performance metrics," said CEO Jeff Hawkins.
The company also announced a list price for its Proteus system of $425,000. But the real head-turner for investors was the look ahead. Quantum-Si said it expects fiscal 2026 revenue of about $1 million. For context, analysts were modeling for over $7 million. That's not a miss; that's a completely different ballpark.
The market's reaction was swift. According to market data, Quantum-Si shares fell 4.51% to 90 cents in after-hours trading following the release.
